肺癌组织中P53蛋白、性激素受体及DNA倍体的测定

目的探讨P53蛋白、雌／孕激素受体、DNA倍体模式在肺癌组织中的表达及其与生物学行为的关系。方法应用免疫组织化学SP法检测40例肺癌患者P53蛋白，雌／孕激素受体的表达，采用流式细胞术法检测细胞核DNA含量。结果40例肺癌P53蛋白、ER／PR表达阳性率分别为67.5％(27／40)，57．5％(23／40)，40．0％(16／40)，异倍体率77．5％(31／40)；P53蛋白、ER／PR的表达与组织学分级有关，且ER／PR表达与病理类型有关；同时P53阳性者DI值高，而ER阳性者DI值低。结论P53蛋白、ER／PR、DNA倍体的联合检测在肺癌的诊断及其恶性程度的评价上有重要意义。

P53 Protein,Estrogen/Progesterone Receptor Expression and DNA Ploidyin Lung Cancer

Objective To study the role of P53 protein,Estrogen/ Progesterone(ER/PR),DNA ploidy and the clinicopathologic features in lung cancer.Methods The expressions of P53 protein and ER/PR were detected in 40 lung cancer specimens with immunohistochemistry method, and DNA ploidy was examined by flow cytometry.Results The positive rates of P53 protein,ER/PR were 67.5%(27/40),57.5%(23/40),40.0%(16/40) respectively in lung cancer.The rate of aneuploidy was 77.5%(31/40).The rate of P53 protein,ER/PR were related to histopathologic grade and the rate of ER/PR was related to the pathlogical classification.In P53 protein postive group and in ER/PR negative group, DI value was higher.Conclusion Simultaneous detections of P53 protein,ER/PR and DNA contents are valuable and play an important role in judging the malignancy of lung cancer patients.